Stone X Group Inc. Humanigen, Inc Transaction History

Stone X Group Inc.

  • $2.06 Trillion
  • Q2 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Aug 13, 2025
BUY
$0.09 - $0.2 $1,272 - $2,826
14,134 New
14,134 $1.7 Million

Others Institutions Holding HGEN

# of Institutions
3
Shares Held
541K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email